The Journal of Pain
Volume 10, Issue 10 , Pages 1001-1011 , October 2009

Translational Pain Research: Achievements and Challenges

  • Jianren Mao

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jianren Mao, MGH Center for Translational Pain Research, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.

References 

  1. Ahmad S, Dray A. Novel G protein-coupled receptors as pain targets. Curr Opin Investig Drugs. 2004;5:67–70
  2. Altier C, Zamponi GW. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci. 2004;25:465–470
  3. Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004;24:10410–10415
  4. Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Curr Opin Investig Drugs. 2008;9:65–75
  5. Basbaum AI. Spinal mechanisms of acute and persistent pain. Reg Anesth Pain Med. 1999;24:59–67
  6. Basbaum AI, Fields HL. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309–338
  7. Becerra L, Breiter HC, Wise R, Gonzalez RG, Borsook D. Reward circuitry activation by noxious thermal stimuli. Neuron. 2001;32:927–946
  8. Beltramo M. Cannabinoid type 2 receptor as a target for chronic-pain. Mini Rev Med Chem. 2009;9:11–25
  9. Bennett G, Deer T, Du Pen S, Rauck R, Yaksh T, Hassenbusch SJ. Future directions in the management of pain by intraspinal drug delivery. J Pain Symptom Manage. 2000;20:S44–S50
  10. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs. 2004;13:1445–1456
  11. Borsook D, Moulton EA, Schmidt KF, Becerra LR. Neuroimaging revolutionizes therapeutic approaches to chronic pain. Mol Pain. 2007;3:25
  12. Bourinet E, Zamponi GW. Voltage gated calcium channels as targets for analgesics. Curr Top Med Chem. 2005;5:539–546
  13. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother. 2006;40:251–260
  14. Burnstock G. Purinergic P2 receptors as targets for novel analgesics. Pharmacol Ther. 2006;110:433–454
  15. Campbell CM, France CR, Robinson ME, Logan HL, Geffken GR, Fillingim RB. Ethnic differences in diffuse noxious inhibitory controls. J Pain. 2008;9:759–766
  16. Campbell JN. Nerve lesions and the generation of pain. Muscle Nerve. 2001;24:1261–1273
  17. Carlton SM, Zhou S, Coggeshall RE. Evidence for the interaction of glutamate and NK1 receptors in the periphery. Brain Res. 1998;790:160–169
  18. Casey KL. Toward a neurophysiology of pain. Headache. 1969;8:141–153
  19. Caterina MJ, Julius D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu Rev Neurosci. 2001;24:487–517
  20. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature. 1997;389:816–824
  21. Chaplan SR, Malmberg AB, Yaksh TL. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther. 1997;280:829–838
  22. Chizh BA, Greenspan JD, Casey KL, Nemenov MI, Treede RD. Identifying biological markers of activity in human nociceptive pathways to facilitate analgesic drug development. Pain. 2008;140:249–253
  23. Chizh BA, Illes P. P2X receptors and nociception. Pharmacol Rev. 2001;53:553–568
  24. Christensen BN, Perl ER. Spinal neurons specifically excited by noxious or thermal stimuli: Marginal zone of the dorsal horn. J Neurophysiol. 1970;33:293–307
  25. Coghill RC, McHaffie JG, Yen YF. Neural correlates of interindividual differences in the subjective experience of pain. Proc Natl Acad Sci U S A. 2003;100:8538–8542
  26. Collis R, Brandner B, Bromley LM, Woolf CJ. Is there any clinical advantage of increasing the pre-emptive dose of morphine or combining pre-incisional with postoperative morphine administration?. Br J Anaesth. 1995;74:396–399
  27. Coluzzi PH. Sublingual morphine: Efficacy reviewed. J Pain Symptom Manage. 1998;16:184–192
  28. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004;64:937–947
  29. Desmeules JA. The tramadol option. Eur J Pain. 2000;4(Suppl A):15–21
  30. Devor M. Neuropathic pain and injured nerve: Peripheral mechanisms. Br Med Bull. 1991;47:619–630
  31. Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, Maixner W. Genetic architecture of human pain perception. Trends Genet. 2007;23:605–613
  32. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci. 1990;11:307–309
  33. Dray A. Inflammatory mediators of pain. Br J Anaesth. 1995;75:125–131
  34. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci. 1993;16:99–104
  35. Dubner R: Neural plasticity and pain following peripheral tissue inflammation or nerve injury. Proceedings of the Vth World Congress on Pain, Pain Research and Clinical Management, Amsterdam, Elsevier, 1991.
  36. Dubner R. Hargreaves KM: The neurobiology of pain and its modulation. Clin J Pain. 1989;5(Suppl 2):S1–S4discussion S4-6
  37. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 1992;15:96–103
  38. Dyck PJ, Thomas PK, Lambert EH, Bunge R. Peripheral Neuropathy. 1st Edition. Philadelphia PA: Saunders; 1984;
  39. Edwards RR, Fillingim RB. Self-reported pain sensitivity: Lack of correlation with pain threshold and tolerance. Eur J Pain. 2007;11:594–598
  40. Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery. 1995;37:1080–1087
  41. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Symptom Manage. 1999;17:384–386
  42. England S. Voltage-gated sodium channels: The search for subtype-selective analgesics. Expert Opin Investig Drugs. 2008;17:1849–1864
  43. Fields HL. Pain. New York: McGraw-Hill; 1987;p 354
  44. Flores CM, Mogil JS. The pharmacogenetics of analgesia: Toward a genetically-based approach to pain management. Pharmacogenomics. 2001;2:177–194
  45. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007;12:113–126
  46. Gladstone JP, Gawel M. Newer formulations of the triptans: Advances in migraine management. Drugs. 2003;63:2285–2305
  47. Gosselin RD, Dansereau MA, Pohl M, Kitabgi P, Beaudet N, Sarret P. Melik Parsadaniantz S: Chemokine network in the nervous system: A new target for pain relief. Curr Med Chem. 2008;15:2866–2875
  48. Gottschalk A, Schroeder F, Ufer M, Oncu A, Buerkle H, Standl T. Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesth Analg. 2001;93:192–196
  49. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: Altered central processing maintained dynamically by peripheral input. Pain. 1992;51:175–194
  50. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract. 1995;49:33–35
  51. Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB, et al. Consensus Working Group of the Sex, Gender, and Pain SIG of the IASP: Studying sex and gender differences in pain and analgesia: A consensus report. Pain. 2007;132(Suppl 1):S26–S45
  52. Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets. 2003;7:737–748
  53. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153:319–334
  54. Guo W, Zou S, Guan Y, Ikeda T, Tal M, Dubner R, et al. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. J Neurosci. 2002;22:6208–6217
  55. Hardy JD. The Nature of Pain. J Chronic Dis. 1956;4:22–51
  56. Hardy JD, Wolff HG, Goodell H. Pain Sensations and Reactions. 1st Edition. Baltimore MD: Williams & Wilkins; 1952;
  57. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27:85–91
  58. Helmy SA, Bali A. The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. Anesth Analg. 2001;92:739–744
  59. Holzer P. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br J Pharmacol. 2008;155:1145–1162
  60. Jain KK. Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs. 2004;5:76–81
  61. James MJ, Cleland LG. Cyclooxygenase-2 inhibitors: What went wrong?. Curr Opin Clin Nutr Metab Care. 2006;9:89–94
  62. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–210
  63. Kaplan KM, Brose WG. Intrathecal methods. Neurosurg Clin N Am. 2004;15:289–296
  64. Klepstad P, Borchgrevink PC. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand. 1997;41:422–426
  65. Lever IJ, Rice AS. Cannabinoids and pain. Handb Exp Pharmacol. 2007;177:265–306
  66. Levine JD, Moskowitz MA, Basbaum AI. The contribution of neurogenic inflammation in experimental arthritis. J Immunol. 1985;135(Suppl 2):843S–847S
  67. Longmore J, Hill RG, Hargreaves RJ. Neurokinin-receptor antagonists: Pharmacological tools and therapeutic drugs. Can J Physiol Pharmacol. 1997;75:612–621
  68. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008;9:2209–2215
  69. Mao J. Translational pain research: Bridging the gap between basic and clinical research. Pain. 2002;97:183–187
  70. Mao J. NMDA and opioid receptors: Their interactions in antinociception, tolerance and neuroplasticity. Brain Res Brain Res Rev. 1999;30:289–304
  71. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain. 2000;87:7–17
  72. Mao J, Chen LL. Gabapentin in pain management. Anesth Analg. 2000;91:680–687
  73. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ. Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res. 1992;598:271–278
  74. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain. 1995;62:259–274
  75. Mao J, Price DD, Mayer DJ, Lu J, Hayes RL. Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res. 1992;576:254–262
  76. McConaghy PM, McSorley P, McCaughey W, Campbell WI. Dextromethorphan and pain after total abdominal hysterectomy. Br J Anaesth. 1998;81:731–736
  77. McMahon SB. Mechanisms of sympathetic pain. Br Med Bull. 1991;47:584–600
  78. McMahon SB, Koltzenburg M. Novel classes of nociceptors: beyond Sherrington. Trends Neurosci. 1990;13:199–201
  79. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277–299
  80. Melzack R, Wall PD. Pain mechanisms: A new theory. Science. 1965;150:971–979
  81. Mendell LM, Wall PD. Responses of Single Dorsal Cord Cells to Peripheral Cutaneous Unmyelinated Fibres. Nature. 1965;206:97–99
  82. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage. 1995;10:564–568
  83. Miljanich GP. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004;11:3029–3040
  84. Muller J. Elements of Physiology. 1st Edition. London UK: Taylor and Walton; 1942;
  85. Neubert JK, Widmer CG, Malphurs W, Rossi HL, Vierck CJ, Caudle RM. Use of a novel thermal operant behavioral assay for characterization of orofacial pain sensitivity. Pain. 2005;116:386–395
  86. Nielsen CS, Staud R, Price DD. Individual differences in pain sensitivity: measurement, causation, and consequences. J Pain. 2009;10:231–237
  87. Noodenbos W. Pain. 1st Edition. Amsterdam: Elsevier; 1959;
  88. Ocana M, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: Present realities and future opportunities. Eur J Pharmacol. 2004;500:203–219
  89. Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: A review. J Am Dent Assoc. 2000;131:184–195
  90. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001;429:71–78
  91. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: Targeting pain at the source. Nat Rev Drug Discov. 2009;8:55–68
  92. Perl ER. Causalgia, pathological pain, and adrenergic receptors. Proc Natl Acad Sci U S A. 1999;96:7664–7667
  93. Perl ER. Cutaneous polymodal receptors: characteristics and plasticity. Prog Brain Res. 1996;113:21–37
  94. Perl ER. Somatic sensation: Transfer and processing of information. 1. Peripheral receptors. Electroencephalogr Clin Neurophysiol. 1969;27:650–651
  95. Porreca F, Lai J, Bian D, Wegert S, Ossipov MH, Eglen RM, et al. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci U S A. 1999;96:7640–7644
  96. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science. 2000;288:1769–1772
  97. Price DD. Psychological and Neural Mechanisms of Pain. 1st Edition. New York NY: Raven; 1988;
  98. Price DD, Hayes RL, Ruda M, Dubner R. Neural representation of cutaneous aftersensations by spinothalamic tract neurons. Fed Proc. 1978;37:2237–2239
  99. Price DD, Long S, Huitt C. Sensory testing of pathophysiological mechanisms of pain in patients with reflex sympathetic dystrophy. Pain. 1992;49:163–173
  100. Price DD, Mao J, Frenk H, Mayer DJ. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain. 1994;59:165–174
  101. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial. Pain. 1998;75:349–354
  102. Raij TT, Forss N, Stancak A, Hari R. Modulation of motor-cortex oscillatory activity by painful Adelta- and C-fiber stimuli. Neuroimage. 2004;23:569–573
  103. Raja SN, Grabow TS. Complex regional pain syndrome I (reflex sympathetic dystrophy). Anesthesiology. 2002;96:1254–1260
  104. Raja SN, Meyer RA, Campbell JN. Peripheral mechanisms of somatic pain. Anesthesiology. 1988;68:571–590
  105. Ren K, Hylden JL, Williams GM, Ruda MA, Dubner R. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain. 1992;50:331–344
  106. Roberts LA, Connor M. TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Pat CNS Drug Discov. 2006;1:65–76
  107. Romero-Sandoval EA, Horvath RJ, DeLeo JA. Neuroimmune interactions and pain: Focus on glial-modulating targets. Curr Opin Investig Drugs. 2008;9:726–734
  108. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454
  109. Sawynok J. Topical analgesics in neuropathic pain. Curr Pharm Des. 2005;11:2995–3004
  110. Silos-Santiago I. The role of tetrodotoxin-resistant sodium channels in pain states: Are they the next target for analgesic drugs?. Curr Opin Investig Drugs. 2008;9:83–89
  111. Simpson RK. Mechanisms of action of intrathecal medications. Neurosurg Clin N Am. 2003;14:353–364
  112. Sinatra R. The fentanyl HCl patient-controlled transdermal system (PCTS): An alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin Pharmacokinet. 2005;44(Suppl 1):1–6
  113. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999;83:389–400
  114. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005;5:315–323
  115. Sollevi A. Adenosine for pain control. Acta Anaesthesiol Scand Suppl. 1997;110:135–136
  116. Sorkin LS. Nociceptive transmission within the spinal cord. Mt Sinai J Med. 1991;58:208–216
  117. Sorkin LS, Westlund KN, Sluka KA, Dougherty PM, Willis WD. Neural changes in acute arthritis in monkeys. IV. Time-course of amino acid release into the lumbar dorsal horn. Brain Res Brain Res Rev. 1992;17:39–50
  118. Storm H. Changes in skin conductance as a tool to monitor nociceptive stimulation and pain. Curr Opin Anaesthesiol. 2008;21:796–804
  119. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci. 2003;23:2899–2910
  120. Talbot JD, Marrett S, Evans AC, Meyer E, Bushnell MC, Duncan GH. Multiple representations of pain in human cerebral cortex. Science. 1991;251:1355–1358
  121. Thomas L, Bledsoe JM, Stead M, Sandroni P, Gorman D, Lee KH. Motor cortex and deep brain stimulation for the treatment of intractable neuropathic face pain. Curr Neurol Neurosci Rep. 2009;9:120–126
  122. Thompson SWN, Woolf CJ: Primary afferent-evoked prolonged potentials in the spinal cord and their central summation: Role of the NMDA receptor. Proceedings of the Vth World Congress on Pain, Amsterdam, Elsevier, 1991.
  123. Toomey M. Gender differences in pain: Does X = Y?. AANA J. 2008;76:355–359
  124. Wadhwa A, Clarke D, Goodchild CS, Young D. Large-dose oral dextromethorphan as an adjunct to patient-controlled analgesia with morphine after knee surgery. Anesth Analg. 2001;92:448–454
  125. Waeber C. Emerging drugs in migraine treatment. Expert Opin Emerg Drugs. 2003;8:437–456
  126. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci. 2005;28:661–669
  127. Watkins LR, Maier SF. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–985
  128. Watkins LR, Maier SF, Goehler LE. Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995;63:289–302
  129. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: What is the therapeutic potential?. BioDrugs. 2008;22:349–359
  130. Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci U S A. 1999;96:7635–7639
  131. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?. Drugs. 1998;55:1–4
  132. Willis WD. Central nervous system mechanisms for pain modulation. Appl Neurophysiol. 1985;48:153–165
  133. Wood JN, Boorman J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr Top Med Chem. 2005;5:529–537
  134. Wood JN, Perl ER. Pain. Curr Opin Genet Dev. 1999;9:328–332
  135. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983;306:686–688
  136. Woolf CJ, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, et al. Towards a mechanism-based classification of pain?. Pain. 1998;77:227–229
  137. Woolf CJ, Chong MS. Preemptive analgesia–treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993;77:362–379
  138. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science. 2000;288:1765–1769
  139. Yaksh TL. Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol Sci. 1999;20:329–337
  140. Yaksh TL. New horizons in our understanding of the spinal physiology and pharmacology of pain processing. Semin Oncol. 1993;20(2 Suppl 1):6–18
  141. Yaksh TL. Spinal pharmacology of pain and its modulation. Clin Neurosurg. 1983;31:291–303
  142. Yamamoto T, Yaksh TL. Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat. Anesthesiology. 1992;77:757–763
  143. Yamamoto T, Yaksh TL. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett. 1992;135:67–70
  144. Yeh CC, Ho ST, Kong SS, Wu CT, Wong CS. Absence of the preemptive analgesic effect of dextromethorphan in total knee replacement under epidural anesthesia. Acta Anaesthesiol Sin. 2000;38:187–193
  145. Zeng Q, Wang S, Lim G, Yang L, Mao J, Sung B, et al. Exacerbated mechanical allodynia in rats with depression-like behavior. Brain Res. 2008;1200:27–38
  146. Zimmermann M, Herdegen T. Plasticity of the nervous system at the systematic, cellular and molecular levels: A mechanism of chronic pain and hyperalgesia. Prog Brain Res. 1996;110:233–259

 Editor's Note: This article is 1 in a series of invited Critical Review articles designed to celebrate The Journal of Pain's 10th year anniversary of publication.

 Supported in part by NIH grants DA 22576, DE 18214, and DA26002.

PII: S1526-5900(09)00573-2

doi: 10.1016/j.jpain.2009.06.002

The Journal of Pain
Volume 10, Issue 10 , Pages 1001-1011 , October 2009

Article Tools